Univariate and multivariate analysis for survival
| Parameter . | Survival . | ||||
|---|---|---|---|---|---|
| n . | UVA . | MVA . | |||
| P . | P . | HR . | 95% CI . | ||
| Age ≥60 y | 8 | .013 | .025 | 2.862 | 1.140-7.183 |
| <60 y | 103 | ||||
| Gender: F | 29 | .24 | — | — | — |
| M | 82 | ||||
| Diagnosis: ALL | 76 | .13 | — | — | — |
| LBL | 35 | ||||
| WBC ≥50.0 (×109/L) | 18 | .009 | — | — | — |
| <50.0 (×109/L) | 93 | ||||
| Hemoglobin <10 (g/dL) | 31 | .36 | — | — | — |
| ≥10 (g/dL) | 80 | ||||
| Platelet <100 (×109/L) | 47 | .036 | — | — | — |
| ≥100 (×109/L) | 64 | ||||
| LDH ≥600 (IU/L) | 79 | .045 | — | — | — |
| <600 (IU/L) | 32 | ||||
| CNS involvement at diagnosis: yes | 6 | .18 | — | — | — |
| No | 105 | ||||
| WHO classification | 111 | .101 | — | — | — |
| ETP-ALL/LBL: yes | 19 | .008 | .023 | 2.275 | 1.117-4.631 |
| No | 92 | ||||
| Treatment received | 111 | .43 | — | — | — |
| Parameter . | Survival . | ||||
|---|---|---|---|---|---|
| n . | UVA . | MVA . | |||
| P . | P . | HR . | 95% CI . | ||
| Age ≥60 y | 8 | .013 | .025 | 2.862 | 1.140-7.183 |
| <60 y | 103 | ||||
| Gender: F | 29 | .24 | — | — | — |
| M | 82 | ||||
| Diagnosis: ALL | 76 | .13 | — | — | — |
| LBL | 35 | ||||
| WBC ≥50.0 (×109/L) | 18 | .009 | — | — | — |
| <50.0 (×109/L) | 93 | ||||
| Hemoglobin <10 (g/dL) | 31 | .36 | — | — | — |
| ≥10 (g/dL) | 80 | ||||
| Platelet <100 (×109/L) | 47 | .036 | — | — | — |
| ≥100 (×109/L) | 64 | ||||
| LDH ≥600 (IU/L) | 79 | .045 | — | — | — |
| <600 (IU/L) | 32 | ||||
| CNS involvement at diagnosis: yes | 6 | .18 | — | — | — |
| No | 105 | ||||
| WHO classification | 111 | .101 | — | — | — |
| ETP-ALL/LBL: yes | 19 | .008 | .023 | 2.275 | 1.117-4.631 |
| No | 92 | ||||
| Treatment received | 111 | .43 | — | — | — |
Diagnosis = ALL vs LBL; treatment received = hyper-CVAD, hyper-CVAD + nelarabine, augmented BFM.
MVA, multivariate analysis; UVA, univariate analysis.